Guardant Health Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GH Nasdaq 2835 https://guardanthealth.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Guardant Health Inc

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - Feb 2nd, 2023 1:05 pm
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina - Feb 2nd, 2023 11:00 am
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 - Feb 1st, 2023 9:05 pm
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery - Jan 31st, 2023 1:05 pm
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer - Jan 30th, 2023 12:05 pm
Guardant Health (NASDAQ:GH) investors are sitting on a loss of 59% if they invested three years ago - Jan 29th, 2023 2:14 pm
Palo Alto-based cancer test developer Guardant Health cuts 130 jobs - Jan 26th, 2023 3:13 pm
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer - Jan 19th, 2023 1:05 pm
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers - Jan 17th, 2023 9:05 pm
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results - Jan 9th, 2023 1:05 pm
Guardant Health Looks Downright Sickly - Dec 28th, 2022 1:49 pm
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference - Dec 28th, 2022 1:00 pm
Three Pharma Stocks to Sell Before They Die - Dec 24th, 2022 10:20 pm
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy - Dec 21st, 2022 1:05 pm
Guardant Health's shares plunged 27% after it released disappointing cancer test results - Dec 16th, 2022 11:24 pm
Guardant Health’s colorectal cancer test lags behind rival Exact Sciences - Dec 16th, 2022 9:36 pm
Maxar, Guardant Health, Faraday, and More Stock Market Movers Today - Dec 16th, 2022 9:21 pm
Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard - Dec 16th, 2022 9:12 pm
This Nasdaq Healthcare Stock's Pain Is Its Rival's Gain - Dec 16th, 2022 5:22 pm
Midday movers: Adobe Systems, Guardant Health, Meta Platforms and more - Dec 16th, 2022 12:35 pm